Annabella Amatulli has more than 14 years’ experience working in pharmaceutical companies, with a focus on regulatory affairs. She holds a BSc in Pharmaceutical Biotechnology and a MS in Biology from the University of Milan and Milan-Bicocca, respectively.
Prior to joining Enterprise Therapeutics, she was Head of Global Regulatory Sciences at Alfasigma, where she contributed to the inorganic growth of the company and the regulatory strategy for all products, across varying phases of development. Annabella has an extensive range of regulatory experience throughout Europe, the US and in other regions of the world including China, Australia and Canada.
Her track record includes obtaining of several approvals such as: Orphan Drug Designation, Fast Track and Breakthrough, Paediatric Investigation Plans, a global early access programme for an orphan drug, and a global registration for a rare disease therapeutic.
Prior to Alfasigma, Annabella held various senior regulatory positions in both SMEs and large pharmas, including Chief Regulatory Officer at Napo Therapeutics and Global Regulatory Affairs Biotech & Development Director at Dompè Farmaceutici, as well as roles within Janssen-Cilag (J&J), Schering-Plough, and Mylan.